VIT-100 was developed by ItherX Pharmaceuticals of San Diego. In preclinical studies, companyl has shown that VIT-100 inhibits the growth of cells taken from multiple keloid biopsies as compared to... It is believed that similar effects would be seen in cells isolated from hypertrophic scars.
- Mechanism
- Curator reviewed
VIT-100 is used for Proliferative Vitreoretinopathy (PVR), a serious eye disease characterized by uncontrolled cellular growth that can lead to retinal detachment and ensuing vision loss. It is expected to reduce the incidence of repeat retinal detachment in patients who undergo surgical repair.
- Primary indication
- Investigated for use/treatment in diabetic retinopathy, scar tissue, and vitreous hemorrhage.Curator reviewed
- Code names
- VIT-100
Which companies are running trials of VIT-100, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account